Global Retinal Neovascularization Market -2023-2030

Global Retinal Neovascularization Market -2023-2030

The Global Retinal Neovascularization Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

The pathological disease is known as retinal neovascularization is defined by the aberrant development of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. If left untreated, this illness, which is linked to a number of eye conditions, can cause severe vision issues or even blindness.

The development of these aberrant blood vessels can result in a number of problems, including scarring, macular edema, and retinal hemorrhages, which can all seriously impair vision. To stop additional vision loss, retinal neovascularization must be diagnosed and treated in a way.

The retinal neovascularization market is significantly influenced by the increased prevalence of diabetes, particularly in emerging economies. A major contributor to retinal neovascularization is diabetic retinopathy, and the number of patients requiring care grows along with the number of diabetics.

Age-related eye disorders including wet age-related macular degeneration (AMD) are more common in the aging population. The need for treatments to control the retinal neovascularization brought on by these disorders is growing as the world's population ages.

Market Dynamics: Drivers

The Increasing Focus on Diabetic Retinopathy

The most prevalent microangiopathic consequence of diabetes mellitus, diabetes retinopathy (DR), affects more than 100 million people globally and is a significant contributor to visual impairment and legal blindness in developed nations. DR is traditionally divided into proliferative (PDR) and non-proliferative (NPDR) types. The progression from NPDR to PDR is marked by the onset of neovascularization, which is characterized by intraretinal hemorrhages, hard and soft exudates, cotton-wool spots, microaneurysms, venous calibre abnormalities, intraretinal microvascular anomalies, and both macular and peripheral capillary nonperfusion.

VEGF enhances the phosphorylation of tight junction proteins, increasing the permeability of retinal capillaries. Additionally, enhanced transcytosis, activated NOS-mediated processes, induced changes of various intercellular molecules, including occludin, catenins, and cadherins, as well as increased transcytosis all contribute to VEGF-related hyperpermeability. All of these VEGF-related phenomena, which are primarily controlled by VEGF-A isoforms, together with an incredibly complicated series of additional activities and mediators cause DME, a common DR-related complication, to start and progress.

The first medication to receive FDA approval for the intravitreal treatment of retinal disorders was pegaptanib (Macugen, Eyetech/Pfizer). This substance is a pegylated aptamer that binds to the heparin-binding domain of VEGF165 isoform with preference.

Limited Patient Awareness

Delays in diagnosis and the start of treatment may result from patients and healthcare professionals being unaware of the signs and dangers of retinal neovascularization. There may be limited availability to specialist eye care facilities and qualified ophthalmologists in some areas, especially in low-resource settings, which might cause treatment to be delayed or fall short of expectations. Treatments for retinal neovascularization, such as anti-VEGF injections, may come with risks and adverse effects like infection, retinal detachment, and increased intraocular pressure. Some patients may choose not to seek therapy because of these dangers.

Segment Analysis

The global retinal neovascularization market is segmented based on product type, end-user, and region.

The anti-VEGF therapies segment accounted for approximately 48.4% of the market share

Aflibercept (Eylea; Regeneron), ranibizumab (Lucentis; Genentech, California), and bevacizumab (Avastin; Genentech) are the most frequently used VEGF-A pathway treatments available for AMD. The approach to treating wet AMD has been changed by anti-VEGF drugs.

Bevacizumab is a fully humanized immunoglobulin G1 (IgG1) molecule of 148 kDa that binds VEGF-A isoforms under the brand name Avastin from Hoffmann-La Roche. This antibody was initially created for the treatment of cancer. Its intravitreal application for retinal conditions is still regarded as ""off-label"" therapy. Bevacizumab functions as a pure anti-VEGF antibody, and its major effects are to inhibit the neovascular stimulation and VEGF-induced enhanced vascular permeability. The mechanisms of action are rather straightforward.

Anti-VEGF medications are considered to be the standard of care for treating wet AMD, but in practice, the expenses associated with treating wet AMD frequently make it difficult to achieve the best possible clinical results. The cost of current anti-VEGF medicines may be reduced by the development of biosimilars, which are biologics with equivalent efficacy and safety to reference biologics.

Despite the fact that anti-VEGF treatment is useful and effective for a variety of retinal illnesses, patients and the healthcare system are significantly burdened by the need for repeated intravitreal medication injections due to their high cost and intrusive nature.

Geographical Analysis

Advanced Healthcare Infrastructure

North America has been a dominant force in the global retinal neovascularization market. Between 1,100 and 1,500 newborns in the U.S. experience ROP that is severe enough to call for medical attention. Infants who are born before 31 weeks of pregnancy or who are under 1,500 grams (3.3 lbs) at birth are frequently affected by this rare eye illness. These newborns are at danger of developing aberrant retinal blood vessels (retinal neovascularization), which could result in retinal detachment and irreversible vision loss. Retinal blood vessels are frequently only fully developed after an infant is full-term (9 months of pregnancy). ROP can sometimes improve on its own in mild cases, but in more severe cases, treatment may be necessary to prevent major blindness and visual impairment.

In June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. launched BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab), in the United States. BYOOVIZ is commercially available from July 2022, through significant distributors throughout the U.S. Healthcare provider involvement, promotional activity, cooperation with professional associations, and patient advocacy groups have already begun. In September 2021, the FDA authorized BYOOVIZ for the treatment of myopic choroidal neovascularization, macular edema following retinal vein occlusion, and neovascular (wet) age-related macular degeneration (AMD).

In April 2023, Adverum Biotechnologies, Inc., a clinical-stage company, stated nonclinical data in support of the two doses of ixoberogene soroparvovec (Ixo-vec, formerly known as ADVM-022) being assessed in the Phase 2 LUNA trial as well as the potential for staggered, bilateral administration in the treatment of wet AMD.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global retinal neovascularization market. There were delays in the detection and treatment of retinal neovascularization and associated eye problems because of lockdowns, restrictions, and patients' anxiety about attending healthcare institutions during the epidemic.

The pandemic may have caused clinical studies for novel therapeutics to be postponed or temporarily stopped, which could have had an impact on the development of new medications and their possible market introduction.

Competitive Landscape

The major global players in the market include Regeneron Pharmaceuticals Inc., Biogen, Notal Vision, Inc., Novartis AG, Adverum Biotechnologies, Inc., Genentech, Inc., Bayer AG, and Others.

Key Developments
• In February 2023, Regeneron Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration has authorized EYLEA (aflibercept) Injection to treat preterm infants with retinopathy of prematurity.

Why Purchase the Report?
• To visualize the global retinal neovascularization market segmentation based on disease type, treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of retinal neovascularization market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global retinal neovascularization market report would provide approximately 55 tables, 56 figures, and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies